Last updated: February 25, 2026
What is the drug identified by NDC: 45802-0042?
The National Drug Code (NDC) 45802-0042 refers to Tavneos (avacopan), marketed by ChemoCentryx. It is approved by the FDA for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis) in adult patients.
Market Overview
Market Size and Demand
The global vasculitis therapeutics market, estimated at approximately USD 600 million in 2021, exhibits growth driven by increased diagnosis rates and R&D investments. ANCA-associated vasculitis is rare but requires targeted immunomodulation.
In the U.S., prevalence estimates suggest roughly 3 to 10 cases per million inhabitants, with approximately 10,000 patients annually eligible for advanced therapies. Given the drug's FDA approval in 2021, adoption has remained steady.
Current Market Participants
- Avacopan (Tavneos): Manufactured by ChemoCentryx
- Rival Agents:
- Rituximab (Rituxan): Used off-label and in combination
- Cyclophosphamide: Traditional immunosuppressant
- Other biologics: Microtubule inhibitors and corticosteroids
Market Penetration
Preliminary data indicates that Tavneos accounts for roughly 25% of vasculitis treatment prescriptions as of mid-2022, with oncological and autoimmune markets posing stiff competition. Its niche target profile limits overall market share but commands premium pricing owing to clinical efficacy.
Price Analysis
Current Pricing
- Average wholesale price (AWP): USD 37,000 per 30-day supply
- Average sales price (ASP): USD 34,500 per 30-day supply
- Net price after rebates and discounts: Estimated at USD 30,000
The pricing reflects the drug's novel mechanism and the high costs associated with biologic manufacture. While comparable biologics like rituximab are priced around USD 25,000–USD 35,000 per treatment course, Tavneos commands a premium due to its targeted mechanism.
Cost Comparison with Alternatives
| Drug |
Typical Course Cost |
Mode of Action |
FDA Approval Year |
Reimbursement Environment |
| Tavneos (avacopan) |
USD 30,000–USD 37,000 |
Complement C5a receptor inhibition |
2021 |
Managed via specialty pharmacy channels |
| Rituximab |
USD 20,000–USD 35,000 |
B-cell depletion |
1997 |
Widely reimbursed under Medicare/insurance |
| Cyclophosphamide |
USD 1,000–USD 2,000 |
Alkylating agent |
1959 |
Low-cost, generic option |
Price Projection Assumptions
- Market penetration: Will increase to 50% by 2025 as clinicians adopt Tavneos for first-line therapy.
- Pricing adjustments: Biologics typically see a 3% annual escalation for inflation and new competitive pressures.
- Reimbursement shifts: Favor increased access due to demonstrated clinical benefits.
Projected Price Trend (Next 3 Years)
| Year |
Estimated Average Price per 30-Day Supply |
Notes |
| 2023 |
USD 34,500 |
Current market price |
| 2024 |
USD 35,500 |
Slight inflation, increased demand |
| 2025 |
USD 36,500 |
Market stabilization, expanding coverage |
Future Market Drivers and Risks
Drivers
- Increasing diagnosis rates of ANCA vasculitis
- Expanding indications for avacopan
- Clinical data supporting superior safety and efficacy
- Payer willingness to reimburse for targeted therapies
Risks
- Competition from biosimilars or generics after patent expiry (not anticipated before 2030)
- Price constraints imposed by payers and policy reforms
- Slow adoption rates due to clinician familiarity with existing therapies
Key Takeaways
- NDC 45802-0042 (Tavneos) is a targeted biologic for ANCA-associated vasculitis.
- The current wholesale price ranges around USD 30,000–USD 37,000 per month.
- Market penetration is growing, expected to reach 50% in the next two years.
- Price projections indicate a gradual increase aligned with inflation and rising demand.
- Competition and payer policies remain significant factors influencing pricing and market share.
FAQs
-
What are the main competitors to Tavneos?
Rituximab and cyclophosphamide are the primary alternative therapies, with rituximab being the most comparable biologic.
-
How does the price of Tavneos compare globally?
International prices vary, generally lower in Europe and Canada due to negotiated reimbursement agreements, averaging USD 20,000–USD 25,000 annually.
-
What factors could significantly alter price projections?
Introduction of biosimilars, regulatory changes, shifts in clinical guidelines, and payer reimbursement policies.
-
When is patent expiry expected for Tavneos?
Patent protections are anticipated to last until approximately 2030, with potential extensions.
-
What is the outlook for new indications?
Ongoing clinical trials aim to expand use to other autoimmune conditions like lupus nephritis, potentially increasing market size and pricing power.
References
[1] ChemoCentryx. (2022). Tavneos (avacopan): FDA approval documentation.
[2] Market Research Future. (2022). Global vasculitis therapeutics market report.
[3] IQVIA. (2022). Retail and specialty pharmacy analysis.
[4] FDA. (2021). Approval letter for Tavneos.
[5] Statista. (2022). Biologic drug pricing trends.
